Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Checkpoint Therapeutics Inc CKPT

Healthcare Biotechnology
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. The Company is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber... see more

Recent & Breaking News (NDAQ:CKPT)

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CKPT

Newsfile June 3, 2024

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Newsfile June 3, 2024

IMPORTANT DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Accesswire June 2, 2024

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

Newsfile June 2, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CKPT

Accesswire June 1, 2024

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Accesswire June 1, 2024

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Accesswire May 31, 2024

TUESDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Newsfile May 31, 2024

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

PR Newswire May 31, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CKPT

PR Newswire May 30, 2024

CKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud Lawsuit

PR Newswire May 30, 2024

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Accesswire May 30, 2024

TUESDAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Newsfile May 30, 2024

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

Newsfile May 29, 2024

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action - CKPT

PR Newswire May 29, 2024

IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Accesswire May 29, 2024

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

Newsfile May 28, 2024

IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

Accesswire May 28, 2024

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action - CKPT

Newsfile May 28, 2024

CKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud Lawsuit

PR Newswire May 28, 2024